Introduction
============

Ozone (O~3~), a common air pollutant, is an asthma trigger. O~3~ causes asthma symptoms, reduces lung function, and causes airway hyperresponsiveness (AHR) ([@r8]; [@r9]; [@r13]). Indeed, emergency department visits and hospital admissions for asthma increase following days of high ambient O~3~ ([@r9]; [@r13]). The majority of the U.S. population is either obese or overweight, and obesity is a risk factor for asthma ([@r6]). Both overweight and obesity increase O~3~-induced decrements in lung function, especially in subjects with pre-existing AHR ([@r1]; [@r3]). Acute O~3~ exposure also increases pulmonary mechanics in obese but not lean mice and causes greater increases in airway responsiveness in obese than lean mice ([@r34]). These observations imply a link between body mass and responses to pollutant triggers of asthma. However, the mechanistic basis for obesity-related changes in pulmonary responses to O~3~ is poorly understood.

O~3~ causes injury to pulmonary epithelial cells ([@r30]), resulting in an inflammatory response that includes increases in bronchoalveolar lavage (BAL) cytokines and chemokines, including TNFα, and neutrophil recruitment to the lungs ([@r15]; [@r21]; [@r34]). We have reported that genetic deficiency in either TNFα or TNFR2 attenuates obesity-related increases in BAL neutrophils after acute O~3~ exposure, but actually exacerbates O~3~-induced AHR in obese mice ([@r34], [@r35]). Hence, other factors must also contribute to obesity-related elevations in the response to O~3~.

IL-33, an IL-1 family cytokine, may be one of these factors. IL-33 signals via a complex composed of ST2, the primary binding receptor, and a coreceptor, IL-1R AcP, leading to MyD88- and IRAK-dependent MAP kinase and NF-κB activation. A soluble form of ST2 (sST2) containing the extracellular portion of ST2 can also be generated by alternative splicing ([@r27]). IL-33 and ST2 are genetically associated with asthma ([@r26]). IL-33 is abundantly expressed in epithelial cells and is released upon cell stress or necrosis ([@r4]), as might be expected after O~3~-induced injury. Indeed, lung IL-33 increases upon O~3~ exposure in lean mice ([@r37]). In addition, exogenous administration of IL-33 to the lungs induces AHR and causes pulmonary neutrophil recruitment in mice ([@r2]; [@r25]), events that also occur after O~3~ exposure. Moreover, these effects of IL-33 involve induction of IL-6, CXCR2 utilizing chemokines, such as CXCL1 and CXCL2, and secretion of type 2 cytokines ([@r2]; [@r25]). Obesity also augments O~3~-induced increases in BAL CXCL1 and CXCL2, and BAL concentrations of the type 2 cytokines, IL-13 and IL-5 ([@r15]; [@r34]). Hence, we examined the hypothesis that IL-33 contributes to obesity-related increases in the response to O~3.~ To do so, we treated lean wildtype (WT) and obese *db/db* mice with an ST2 blocking or isotype antibody prior to O~3~ exposure. Our results indicate that IL-33 contributes to the augmented response to O~3~ in obese mice and that innate lymphoid cells type 2 (ILC2), important targets of IL-33 ([@r2]), are activated by O~3~ exposure in obese mice. However, we show that IL-13 producing γδ T cells are also targets of IL-33 and that γδ T cells are required for augmented responses to O~3~ in obese mice. To our knowledge, this is the first report that *pulmonary* γδ T cells express the IL-33 receptor, ST2, and can produce IL-13.

Methods
=======

Animals
-------

Female *db/db* mice, which lack the longform of the receptor for the satiety hormone, leptin, and age-matched WT mice (C57BL/6J) were purchased from Jackson Laboratory (Bar Harbor, ME) at 6 weeks old and acclimated in our vivarium for 4 weeks, when the *db/db* mice weighed twice as much as WT mice. Breeding pairs of WT or TCRδ^--/--^ were purchased from Jackson Laboratory and bred in house. After weaning, WT and TCRδ^--/--^ mice were placed on either a high-fat diet (HFD) in which 60% of calories derive from fat (D12451, Research Diets) or normal mouse chow (PicoLab 5053, LabDiet) in which about 13% of calories derive from fat. Mice were maintained on these diets for 24 weeks, at which time HFD-fed mice were obese. There was no difference in body mass in TCRδ^--/--^ and WT mice fed chow (31.6 ± 0.7 versus 32.3 ± 0.7 g, respectively), but HFD-fed TCRδ^--/--^ mice, though still obese, weighed less than HFD-fed WT mice (46.6 ± 0.9 versus 52.1 ± 1.2 g respectively, *p* \< 0.01). All protocols were approved by the Harvard Medical Area Standing Committee on Animals. Animals were treated humanely and with regard for alleviation of suffering.

Protocol
--------

To assess the role of IL-33 in pulmonary responses to O~3~, WT and *db/db* mice were treated with an antibody directed against the extracellular domain of recombinant murine ST2 (10 mg/kg, i.p.) or with isotype (IgG1) antibodies. At this dose, anti-ST2 blocks responses to exogenous IL-33 in mice ([@r29]). Mice were exposed to O~3~ 24 hr later, and evaluated 24 hr after exposure. Evaluation included measurement of airway responsiveness, BAL, and lung tissue and blood harvest.

To evaluate the role of CD4 cells in O~3~-induced changes in type 2 cytokines, we depleted CD4 cells. *Db/db* mice were injected once with anti-CD4 (clone: GK1.5, Biolegend) (8 mg/kg) or isotype antibody ([@r32]). Mice were exposed to O~3~ 6 days later and evaluated as described above. Confirmation of CD4 depletion in lung tissue was assessed by flow cytometry.

To examine the role of γδ T cells in obese mice, WT and TCRδ^--/--^ mice were fed either an HFD or normal chow, and then exposed to air or to O~3~, and evaluated as described above.

Methods for BAL, measurement of cytokines and chemokines, RNA extraction and RT-qPCR, and flow cytometry were as previously described ([@r18]; [@r34]) and are found in an online supplement (see "Supplemental Methods" in the Supplemental Material).

Ozone Exposure
--------------

Mice were placed in individual wire mesh cages without access to water or food and acutely exposed to air or O~3~ (2 ppm for 3 hr) as described by [@r34]. Immediately upon cessation of exposure mice were transferred to regular cages with free access to food and water.

Measurement of Airway Responsiveness
------------------------------------

Mice were anesthetized and instrumented for measurement of pulmonary mechanics and airway responsiveness to methacholine, using the forced oscillation technique, as previously described by [@r35]. A positive end expiratory pressure of 3 cm H~2~O was applied and the chest wall opened to expose the lungs to atmospheric pressure. Changes in total pulmonary resistance (R~L~), Newtonian resistance (Rn), which mainly reflects changes in the mechanical properties of the airways, and the coefficients of lung tissue damping (G) and lung tissue elastance (H), measures of changes in the lung periphery, including airway closure, were assessed after aerosolized saline and after increasing doses of aerosolized methacholine.

Statistics
----------

Data were analyzed by factorial ANOVA using STATISTICA software (StatSoft®, Tulsa, OK) with mouse genotype, antibody treatment, and exposure or mouse genotype, diet, and exposure as main effects. Fisher's least significant difference test was used as a post-hoc test. BAL cells and flow cytometry data were log transformed prior to statistical analysis in order to conform to a normal distribution. A *p*-value \< 0.05 was considered statistically significant.

Results
=======

IL-33 Contributes to Pulmonary Responses to O~3~ in Obese but not Lean Mice
---------------------------------------------------------------------------

Compared to air, O~3~ exposure increased BAL IL-33, but the effect was significantly greater in obese *db/db* mice than in lean WT mice ([Figure 1A](#f1){ref-type="fig"}). In contrast, serum IL-33 was unchanged by obesity (7.1 ± 0.8 versus 6.0 ± 0.7 pg/mL in O~3~-exposed *db/db* versus WT mice, respectively) and was approximately 50% lower after O~3~ than air in both WT and *db/db* mice (data not shown).

![Role of IL-33 in pulmonary responses to O~3~ exposure in obese mice. (*A*) Bronchoalveolar lavage (BAL) IL-33 and (*B*) changes in pulmonary resistance (R~L~) induced by inhaled aerosolized methacholine in lean wildtype (WT) and obese *db/db* female mice exposed to air or ozone (O~3~) (2 ppm for 3 hr) and studied 24 hr after exposure. (*C*) Airway responsiveness to methacholine assessed using G, the coefficient of lung tissue damping, and (*D*) BAL neutrophils in a different cohort of WT and *db/db* treated with isotype or anti-ST2 antibody prior to O~3~ exposure. For panels *A* and *B*, results are mean ± SE of 4--8 mice/group studied over 16 experimental days. For panels *C* and *D*, results are mean ± SE of 4--8 mice/group studied over 8 experimental days. \**p* \< 0.05 versus air. ^\#^ *p* \< 0.05 versus lean mice with same exposure. ^†^ *p* \< 0.05 versus isotype-treated mice of same genotype.](EHP272.g001){#f1}

In air exposed mice, baseline pulmonary resistance (R~L~) was greater in *db/db* than WT mice (PBS values in [Figure 1B](#f1){ref-type="fig"}) consistent with the smaller lungs of the *db/db* mice ([@r21]). O~3~ increased baseline R~L~ in *db/db* but not WT mice ([Figure 1B](#f1){ref-type="fig"}). O~3~ also increased methacholine-induced changes in R~L~ to a greater extent in *db/db* than WT mice ([Figure 1B](#f1){ref-type="fig"}). Essentially similar results were observed for the coefficients of G and for elastance H, measures of the lung periphery and for Rn, a measure of the central airways (see Figure S1A--C). However, the effect was greatest for G, suggesting that the effects of O~3~ are largely mediated in the lung periphery. Consequently, in subsequent analyses of airway responsiveness, methacholine-induced changes in G are presented.

Effects of anti-ST2 treatment were assessed in a separate cohort of WT and *db/db* mice exposed to O~3~. Compared to isotype antibody, anti-ST2 treatment had no effect on airway responsiveness in O~3~-exposed WT mice ([Figure 1C](#f1){ref-type="fig"}). However, in O~3~-exposed *db/db* mice, anti-ST2 treatment significantly reduced baseline G, and significantly reduced airway responsiveness ([Figure 1C](#f1){ref-type="fig"}). Similar results were obtained for R~L~ (see Figure S1D). BAL neutrophils were greater in O~3~-exposed *db/db* versus WT mice ([Figure 1D](#f1){ref-type="fig"}) treated with isotype antibody. Anti-ST2 significantly reduced BAL neutrophils in *db/db* but not in WT mice. Taken together, the results indicate a role for IL-33 in responses to O~3~ in obese mice. In contrast, we observed no significant effect of anti-ST2 versus isotype antibody treatment on airway responsiveness in air-exposed *db/db* mice (see Figure S1E).

IL-33 Dependent BAL Cytokines and Chemokines
--------------------------------------------

Others have reported that exogenously administered IL-33 causes AHR and increases BAL neutrophils by inducing both type 2 cytokines like IL-13 and IL-5, chemokines that utilize CXCR2, like CXCL1 and CXCL2, and IL-6 ([@r2]; [@r5]; [@r25]). O~3~ exposure significantly increased BAL concentrations of the type 2 cytokines IL-5, IL-13, and IL-9 in *db/db* but not WT mice ([Figure 2A--C](#f2){ref-type="fig"}). Similar results were obtained in obese *Cpe^fat^* mice versus their WT controls ([@r34]). In addition to IL-33, two other epithelial derived cytokines, IL-25 and TSLP, can also induce the secretion of type 2 cytokines. However, neither *Il25* nor *Tslp* expression was affected by O~3~ exposure (data not shown). In addition to IL-5, IL-13 and IL-9, O~3~ also caused greater increases in BAL CXCL1, IL-6, IL-2, eotaxin (CCL11), CSF3, IL-1α, IL-10, IL-12 (p40), CXCL10, LIF, RANTES, CXCL9, and CCL4 in the same cohort of O~3~-exposed isotype-treated *db/db* versus WT mice ([Figure 2D--P](#f2){ref-type="fig"}). Of these, BAL concentrations of IL-5, IL-13, IL-6, CXCL1 and CCL4 were significantly reduced in anti-ST2 versus isotype treated *db/db* mice exposed to O~3~ ([Figure 3A--E](#f3){ref-type="fig"}). A similar effect of anti-ST2 was observed on BAL IL-9, but did not reach statistical significance ([Figure 3F](#f3){ref-type="fig"}). ST2-dependent changes in these cytokines and chemokines ([Figure 3](#f3){ref-type="fig"}) likely contribute to the ST2- dependent effects of O~3~ observed in obese mice ([Figure 1C,D](#f1){ref-type="fig"}).

![Obesity augments O~3~-induced increases in BAL cytokines, chemokines, and growth factors. BAL (*A*) IL-5, (*B*) IL-13, (*C*) IL-9, (*D*) CXCL1, (*E*) IL-6, (*F*) IL-2, (*G*) eotaxin (CCL11), (*H*) CSF3, (*I*) IL-1α, (*J*) IL-10, (*K*) IL-12 (p40), (*L*) CXCL10, (*M*) LIF, (*N*) RANTES, (*O*) CXCL9, and (*P*) CCL4 in a cohort of WT and *db/db* treated with isotype antibody prior to air or O~3~ exposure. Samples that were undetectable were assigned a value of 0. Limit of detection (LOD) indicates that all samples in the group were below the limit of detection. Note: Results are mean ± SE of 4--7 mice/group studied over 16 experimental days. \**p* \< 0.05 versus air. ^\#^ *p* \< 0.05 versus lean mice with same exposure.](EHP272.g002){#f2}

![Anti-ST2 reduces BAL cytokines and chemokines in obese O~3~-exposed mice. *Db/db* mice were treated intraperitoneal with ST2-blocking or isotype antibodies 24 hr prior to O~3~ exposure (2 ppm for 3 hr). BAL concentrations of (*A*) IL-5, (*B*) IL-13, (*C*) IL-6, (*D*) CXCL1, (*E*) CCL4, and (*F*) IL-9 were measured by ELISA or by multiplex using BAL that had been concentrated five times. Note: Results are the mean ± SE of 6--10 mice/group studied over 8 experimental days. \**p* \< 0.05 versus isotype treated mice.](EHP272.g003){#f3}

Cellular Sources of Type 2 Cytokines
------------------------------------

O~3~ causes IL-6 and CXCL family chemokine release from airway epithelial cells and macrophages ([@r16]; [@r23]). These cells are the likely targets of ST2-mediated changes in IL-6 and CXCL1 ([Figure 3](#f3){ref-type="fig"}). Indeed, both epithelial cells and macrophages express ST2 and can respond to IL-33 ([@r4]; [@r36]; [@r38]). Regarding the cellular source of the observed IL-33-dependent type 2 cytokines ([Figure 3A,B,F](#f3){ref-type="fig"}), many cells in the lung, including Th2 cells, macrophages, mast cells, and innate lymphoid cells type 2 (ILC2), have the capacity to release type 2 cytokines after IL-33 stimulation ([@r5]; [@r27]). γδ T cells also express receptors for IL-33 ([@r7]) and can produce type 2 cytokines ([@r12]), though effects of IL-33 on γδ T cell production of type 2 cytokines have not previously been described. We were unable to detect changes in IL-13^+^ macrophages in obese mice after O~3~ exposure using flow cytometry, nor could we find any evidence of acute mast cell activation within the airways of obese O~3~-exposed mice using ELISA assay of BAL mast cell tryptase (data not shown) suggesting instead a lymphoid source for the observed changes in type 2 cytokines.

IL-13^+^ Th2 cells are elevated in lungs of obese versus lean mice exposed to O~3~ ([@r34]). To examine the contribution of CD4^+^ cells to the elevations in BAL type 2 cytokines observed in obese O~3~-exposed mice, we depleted these cells with an anti-CD4 antibody. Flow cytometry indicated an approximate 75% reduction in lung CD4^+^ cells, confirming the efficacy of the depletion strategy (see Figure S2A). However, BAL type 2 cytokines were not significantly reduced in O~3~-exposed *db/db* mice treated with anti-CD4 versus isotype antibody (see Figure S2B--D), suggesting that Th2 cells were not the source of the elevated BAL type 2 cytokines observed in these mice ([Figure 2](#f2){ref-type="fig"}), nor were other ST2 dependent cytokines (CXCL1, IL-6, CCL4) affected (see Figure S2E--G). In addition, depletion of CD4 cells had no effect on ozone-induced AHR or BAL neutrophils (see Figure S2G,H).

Instead, ILC2 and/or γδ T cells appear to account for IL-33 dependent changes in BAL type 2 cytokines observed in obese O~3~-exposed mice. Flow cytometry indicated no change with obesity or O~3~ in the total number of pulmonary ILC2s ([Figure 4A](#f4){ref-type="fig"}). However, there was an increase in cytokine production by ILC2: O~3~ increased the number of IL-5^+^ and IL-13^+^ ILC2s in obese *db/db* but not lean wildtype mice ([Figure 4B,C](#f4){ref-type="fig"}; see also Figures S3 and S4), consistent with the observed changes in BAL IL-5 and IL-13 ([Figure 2A,B](#f2){ref-type="fig"}). O~3~ also increased the number of pulmonary IL-13^+^ γδ T cells in *db/db* but not WT mice ([Figure 4E](#f4){ref-type="fig"}). Total pulmonary γδ T cells were not affected by obesity but were increased by O~3~ in both *db/db* and WT mice ([Figure 4D](#f4){ref-type="fig"}). O~3~ also increased IL-13^+^ γδ T cells in mice with dietary obesity but not in lean controls ([Figure 4F](#f4){ref-type="fig"}). IL-5^+^ γδ T cells were not assessed. Importantly, after O~3~ exposure, BAL IL-5 and IL-13 were lower in obese TCRδ^--/--^ mice, which lack γδ T cells, than in obese WT mice ([Figure 5A,B](#f5){ref-type="fig"}), indicating that γδ T cells likely contributed to increases in these cytokines observed in obese O~3~ exposed mice ([Figure 2](#f2){ref-type="fig"}). Because type 2 cytokines were also dependent on ST2 ([Figure 3](#f3){ref-type="fig"}), we determined whether γδ T cells can respond to IL-33. Importantly, some pulmonary γδ T cells expressed the ST2 receptor (see Figure S5) and the number of ST2^+^ γδ T cells was greater in O~3~ than in air exposed mice ([Figure 4G](#f4){ref-type="fig"}). To confirm that these ST2^+^ γδ T cells could produce IL-13, we co-stained lung cells with antibodies to both ST2 and IL-13. In these experiments, only O~3~-exposed *db/db* mice were used, since we observed little or no IL-13 in air exposed mice or in WT mice exposed to O~3~ ([Figure 2B](#f2){ref-type="fig"}). Our data indicate that approximately 5 ± 1.5% (*n* = 3) of the γδ T cells in O~3~-exposed *db/db* mice were IL-13^+^. Importantly, virtually all (\> 85%) of these IL-13^+^ γδ T were also ST2^+^ (see Figure S5).

![O~3~ increases IL-5^+^ and IL-13^+^ ILC2 cells and IL-13^+^ γδ T cells in obese mice. Flow cytometry was used to assess (*A*) total and (*B* and *C*) activated lung ILC2s in*db/db*and WT mice exposed to air or O~3~. Total ILC2 cells were gated as negative for lineage markers and positive for CD45, ST2, Thy1.2, and CD127. IL-5^+^ and IL-13^+^ ILC2 cells were gated as negative for lineage markers and positive for CD45 and (*B*) IL-5 or (*C*) IL-13 as shown in Figures S3 and S4. Flow cytometry was also used to assess (*D*) total γδ T as gated as positive for CD45, CD3, and TCRδ. (*E*) IL-13+ γδ T cells in air- and O~3~-exposed WT and *db/db* or (*F*) high fat diet (HFD) and chow-fed mice. IL-13^+^ γδ T cells were gated as positive for IL-13, CD45, CD3, and TCRδ. (*G*) ST2^+^ γδ T cells in air- and O~3~-exposed WT and *db/db* mice. ST2^+^ γδ T cells were gated as SSC^low^TCRδ^+^ST2^+^ as shown in Figure S5. Note: Results are the mean ± SE of 4--9 mice/group studied over 3 experimental days. \**p* \< 0.05 versus air. ^\#^ *p* \< 0.05 versus WT mice with the same exposure.](EHP272.g004){#f4}

![γδ T cells are required for O~3~-induced increases in type 2 cytokines in obese mice. BAL IL-5 (*A*) and IL-13 (*B*) from O~3~-exposed HFD fed WT and TCRδ^--/--^ mice. IL-13 and IL-5 were measured by ELISA after approximately 5× concentration of BAL fluid. (*C*) BAL IL-33 in air and O~3~-exposed chow and HFD fed WT and TCRδ^--/--^ mice. Airway responsiveness, assessed using the coefficient of lung tissue damping--G, and the number of BAL neutrophils in obese (HFD) and lean (chow) WT mice exposed to air or O~3~ (*D*) or WT and TCRδ^--/--^ mice fed a chow or HFD diet and exposed to air or O~3~ (*E*); and airway responsiveness in WT and TCRδ^--/--^ mice fed a chow or HFD diet and exposed to O~3~ (*F*). Note: Results are the mean ± SE of 4--9 mice/group studied over 15 experimental days. \**p* \< 0.05 versus air. ^\#^ *p* \< 0.05 versus lean mice with same exposure. ^†^ *p* \< 0.05 WT versus TCRδ^--/--^ mice with same diet and exposure.](EHP272.g005){#f5}

Whereas γδ T cell deficiency reduced BAL type 2 cytokines, it did not affect BAL CXCL1 or IL-6 in obese O~3~ exposed mice (data not shown), indicating that other IL-33 target cells, perhaps epithelial cells or macrophages, are the source of these ST2-dependent cytokines. The reduction in BAL IL-5 and BAL IL-13 in obese TCRδ^--/--^ versus obese WT mice exposed to O~3~ ([Figure 5A,B](#f5){ref-type="fig"}) was not because of differences in the ability of TCRδ^--/--^ versus WT mice to generate IL-33: BAL IL-33 was not lower in obese TCRδ^--/--^ versus obese WT mice exposed to O~3~ ([Figure 5C](#f5){ref-type="fig"}), although O~3~ caused greater increases in BAL IL-33 in obese HFD versus lean chow fed mice ([Figure 5C](#f5){ref-type="fig"}), as it did in *db/db* versus WT mice ([Figure 1A](#f1){ref-type="fig"}).

O~3~ caused greater increases in airway responsiveness ([Figure 5D](#f5){ref-type="fig"}) and greater increases in BAL neutrophils ([Figure 5E](#f5){ref-type="fig"}) in HFD than chow fed mice, similar to the results obtained in genetically obese mice ([Figure 1](#f1){ref-type="fig"}). Importantly, after O~3~, both airway responsiveness ([Figure 5F](#f5){ref-type="fig"}) and BAL neutrophils ([Figure 5E](#f5){ref-type="fig"}) were lower in obese TCRδ^--/--^ than obese WT mice. Taken together, our data indicate that γδ T cells are required for the augmented responses to O~3~ observed in obese mice, perhaps as a consequence of their ability to produce type 2 cytokines in response to IL-33. Of note, although HFD fed TCRδ^--/--^ mice weighed somewhat less than HFD fed WT mice, multiplex analysis indicated no significant difference in serum cytokines and chemokines in these two groups of mice after air exposure except for an *increase* in serum IL-1α in the HFD fed TCRδ^--/--^ mice (data not shown). The data suggest that the difference in body mass in the two groups of HFD fed mice may did not appear to be biologically significant.

Discussion
==========

Our data indicate that the augmented responses to O~3~ observed in obese mice are partially dependent on IL-33 ([Figure 1](#f1){ref-type="fig"}). IL-6, CXCL1, and type 2 cytokines likely contributed to the effects of IL-33 ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}), and we identified ILC2s and γδ T cells as sources of IL-33 dependent type 2 cytokines in obese O~3~-exposed mice ([Figures 4](#f4){ref-type="fig"} and [5](#f5){ref-type="fig"}). Finally, we demonstrated that γδ T cell deficiency reduced obesity-related increases in the response to O~3~, and reduced associated type 2 cytokine production ([Figure 5](#f5){ref-type="fig"}).

IL-33 contributed to obesity-related increases in the response to O~3~: BAL IL-33 was greater in obese than lean O~3~ exposed mice ([Figures 1A](#f1){ref-type="fig"} and [5C](#f5){ref-type="fig"}) and anti-ST2 reduced O~3~-induced increases in baseline mechanics, in airway responsiveness, and in BAL neutrophils in obese but not lean mice ([Figure 1C,D](#f1){ref-type="fig"}). Effects of IL-33 on the neutrophil chemotactic factors, CXCL1 and IL-6, are likely involved in the changes in BAL neutrophils ([Figure 1D](#f1){ref-type="fig"}): both CXCL1 and IL-6 were elevated in O~3~-exposed obese versus lean mice ([Figure 2D,E](#f2){ref-type="fig"}) and reduced in these mice by anti-ST2 treatment ([Figure 3](#f3){ref-type="fig"}), and both IL-6 and CXCL1 are required for O~3~-induced increases in BAL neutrophils, including in obese mice ([@r14]; [@r20]). Furthermore, exogenous IL-33 induces IL-6 and CXCL1 expression in the lungs ([@r25]). However, reductions in IL-13 by anti-ST2 ([Figure 3A](#f3){ref-type="fig"}) may have also contributed to the anti-ST2-dependent reduction in BAL neutrophils ([Figure 1D](#f1){ref-type="fig"}), since anti-IL-13 also reduces BAL neutrophils in obese O~3~-exposed mice ([@r34]). A role for IL-13 would also explain the efficacy of anti-ST2 in *db/db* but not wildtype mice, since O~3~ increased BAL IL-13 only in the obese mice ([Figure 2](#f2){ref-type="fig"}), consistent with previous observations in obese *Cpe^fat^* mice ([@r34]).

Anti-ST2 also attenuated O~3~-induced increases in baseline pulmonary mechanics in *db/db* mice ([Figure 1C](#f1){ref-type="fig"}; see also Figure S1D). A similar reduction is observed after anti-IL-13 in obese mice ([@r34]), suggesting that IL-33-dependent increases in IL-13 contributed to obesity-related increases in effects of O~3~ on baseline pulmonary mechanics ([Figure 1B](#f1){ref-type="fig"}, PBS values). However, blocking IL-13 does not reduce AHR in O~3~-exposed obese mice ([@r34]), whereas blocking ST2 did ([Figure 1C](#f1){ref-type="fig"}). Thus, other IL-33-driven factors must also have a role. IL-9 may be one of these factors. IL-9 is ST2-dependent ([@r10]), was increased by O~3~ in obese but not lean mice ([Figure 2C](#f2){ref-type="fig"}), and can induce AHR ([@r11]). Chemokines such as CXCL1, which was reduced in anti-ST2 versus isotype treated obese mice ([Figure 3D](#f3){ref-type="fig"}), may also contribute to the observed ST2-dependent effects on AHR in obese mice: blocking CXCR2 reduces AHR induced by exogenous IL-33 ([@r25]), and CXCR2 is required for O~3~-induced AHR in lean mice ([@r14]).

BAL IL-5 and IL-13 were reduced in anti-ST2 versus isotype antibody treated obese mice exposed to O~3~ and a similar trend was observed for IL-9 ([Figure 3](#f3){ref-type="fig"}), indicating a requirement for IL-33 in the induction of these type 2 cytokines by O~3~. Of note, although we did find increased type 2 cytokines we could not find eosinophils in the BAL or lung tissue of either obese or lean mice after O~3~. Our data provided little evidence that macrophages, mast cells, or CD4^+^ T cells were the IL-33 target cells involved in production of type 2 cytokines in obese mice after O~3~, although we cannot rule them out entirely. Indeed, because *db/db* mice have thymic atrophy ([@r28]), it is possible that in other types of obese mice, CD4^+^ cells do play a role in the type 2 cytokine production observed following O~3~. However, in *db/db* mice, ILC2s and γδ T cells were the likely sources of these cytokines. O~3~ increased IL-5^+^ and IL-13^+^ ILC2 cells in lungs of obese but not lean mice after O~3~ ([Figure 4B,C](#f4){ref-type="fig"}; see also Figure S4) without changes in the total number of ILC2s ([Figure 4A](#f4){ref-type="fig"}; see also Figure S3). A recent report indicates that O~3~ can also induce type 2 cytokine production from ILC2s from lungs of lean BALB/c mice ([@r37]). Importantly, the authors also noted that lean BALB/c mice had substantive increases in BAL IL-5 release after O~3~, whereas lean C57BL/6 mice had only minimal changes in BAL IL-5, consistent with our observations with the latter strain ([Figure 2A](#f2){ref-type="fig"}). Importantly, reconstitution of lung ILC2s into mice lacking these cells restores their ability to develop AHR after O~3~ exposure, indicating that activation of ILC2 by O~3~ does indeed have the capacity to cause AHR ([@r37]). ILC2 also appear to be the source of type 2 cytokines induced by O~3~ exposure in the nose ([@r19]). Taken together, the data extend the list of asthma triggers that can induce ILC2 activation to include not only allergy and viral infection ([@r5]; [@r33]), but also O~3~, and IL-33 seems to be a common denominator inducing their activation in each instance.

We also observed increased IL-13^+^ γδ T cells in obese but not lean mice after O~3~ exposure ([Figure 4E,F](#f4){ref-type="fig"}). Importantly, these cells also expressed ST2 (see Figure S5). γδ T cells produce type 2 cytokines in other tissues ([@r12]; [@r31]) and undergo proliferation in response to IL-33 ([@r7]). However, to our knowledge, these data are the first to show that pulmonary γδ T cells can produce IL-13 ([Figure 4E,F](#f4){ref-type="fig"}) and that IL-33 can induce IL-13 expression in γδ T cells. BAL IL-5 and IL-13 were reduced in obese TCRδ^--/--^ versus WT mice after O~3~ exposure ([Figure 5A,B](#f5){ref-type="fig"}). These reductions could be the result of factors produced from γδ T cells acting to promote type 2 cytokine expression in ILC2s. However, given our observations that γδ T cells expressed ST2 receptors, especially after O~3~ ([Figure 5F](#f5){ref-type="fig"}; see also Figure S5), and that IL-13^+^ γδ T cells were also ST2^+^ (see Figure S5), our data are consistent with the hypothesis that γδ T cells are themselves a source of ST2-dependent IL-13 and IL-5 in obese O~3~-exposed mice. Follow up experiments will be required to determine the relative roles of ILC2 versus γδ T cells in these events. Others have also reported a role for γδ T cells in O~3~-induced AHR in lean mice ([@r17]; [@r22]). The ability of γδ T cells to express ST2 receptors and produce type 2 cytokines now needs to be considered in experimental interventions designed to identify the cellular locus of action of IL-33.

Recent reports by others indicate profound systemic effects of O~3~ exposure that include elevations in circulating glucose and lipids ([@r24]). Hence, we cannot rule out the possibility that the observed effects of γδ T cell deficiency ([Figure 5](#f5){ref-type="fig"}) and anti-ST2 ([Figures 1](#f1){ref-type="fig"} and [3](#f3){ref-type="fig"}) were the result of systemic rather than pulmonary effects of O~3~ in obese mice. However, as IL-33 was reduced in the blood, but increased in BAL after O~3~ exposure, the observed effects of IL-33 were more likely the result of IL-33 released in the lung.

In summary, IL-33 contributed to the augmented responses to O~3~ observed in obese mice. Obesity and O~3~ also interacted to induce type 2 cytokine expression in ILC2s and γδ T cells, and these cells appear to contribute to the effects of IL-33, though other cellular targets of IL-33 may also be involved. There was little or no role for IL-33 in lean mice. Thus, our results also highlight obesity-related differences in the regulation of responses to O~3~, and emphasize the need for greater understanding of the effects of O~3~ in obese subjects, who now make up a substantial proportion of the U.S. population.
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